-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recovery plasma has been used to treat respiratory infections for more than 100 years, and during the 1918 influenza pandemic, plasma or serum has been widely used in recovery patients.
plasma in patients with neo-coronary pneumonia is a common method of clinical treatment, but its efficacy varies greatly, possibly due to significant differences in antibody levels.
In China, for the new coronary pneumonia, early use of recovery plasma treatment, but there is no strict randomized controlled trial, see: JAMA: recovery plasma treatment COVID-19 possibilities and challenges, at the same time, the domestic also issued a special consensus: the recovery period of the new coronary pneumonia recovery plasma clinical treatment program (trial second version), but the recovery period plasma for the new coronary pneumonia can be described as a wave of three folds.
In previous studies, no significant differences were observed in clinical status or overall mortality between patients treated with recovery plasma and those receiving a placebo, as detailed in: NEJM: Recovery Plasma in New Crown Patients - Overrated Antibody Therapy.
The study was supported by a separate study, published in BMJ, detailing: BMJ: Assessment of the therapeutic effectiveness of recovery plasma in patients hospitalized with moderate neocyctic pneumonia This study further looked at the relationship between antibody levels in recovery plasma and the risk of death in patients.
this study, a retrospective study of U.S. national registration data, researchers measured levels of anti-SARS-Cov-2 IgG antibodies in recovery plasma used to treat Patients hospitalized with Covid-19, using Vitros anti-SARS-Cov-1 2IgG chemical luminescent immunoanalysis evaluates serum binding antibody levels, defining plasma antibody levels below 4.62 as low, moderate at 4.62-18.45, and high above 18.45.
the main endpoint of the study was the death of patients 30 days after plasma therapy.
3082 patients participated in the study, 515 patients received high-titration antibody plasma treatment, 2006 patients received medium-titration antibody plasma treatment, and 561 patients received low-titration antibody plasma treatment, the number of 30-day deaths in each group was 115, 549 and 166 (22.3% vs27.4% vs. 29.6%).
After adjusting mechanical aeration, the level of antibody in the treatment plasma was moderately related to the risk of death in patients who did not receive mechanical aeration, and the risk of death in patients in the high-titration antibody plasma treatment group was lower than in the low-titration antibody treatment group (RR=0.66), but in patients receiving mechanical aeration, the effect of high-titration antibody plasma therapy was not significant (RR=1.02).
study concluded that for patients hospitalized with new coronary pneumonia who did not receive mechanical aeration, receiving high-titration antibody plasma therapy could help them recover.
Mays medicine believes that the exploration of scientific problems is endless, can not be given up or affirmed because of the success or failure of the moment, from the recovery of plasma cases can be seen, neither mythical this method, nor because part of the study is negative results and abandon it, to rational and dialectical view of clinical problems, and in-depth exploration.